Hepatocellular carcinoma: epidemic and treatment

Jill Allen; Alan Venook

doi:10.1007/s11912-004-0047-9

Hepatocellular carcinoma: epidemic and treatment

Curr Oncol Rep. 2004 May;6(3):177-83. doi: 10.1007/s11912-004-0047-9.

Authors

Jill Allen¹, Alan Venook

Affiliation

¹ Division of Gastrointestinal Oncology, University of California at San Francisco School of Medicine, UCSF Medical Center, 1600 Divisadero, Box 1705, San Francisco, CA 94115-1610, USA.

PMID: 15066228
DOI: 10.1007/s11912-004-0047-9

Abstract

Hepatocellular carcinoma remains a worldwide epidemic. Survival rates are poor; however, oncologists are able to offer regional therapies to those patients who present with early disease. Prevention through vaccination remains a mainstay of this epidemic. New staging systems that incorporate important information about tumor characteristics and liver disease improve our ability to prognosticate and treat these patients.

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Hepatocellular / drug therapy
Carcinoma, Hepatocellular / epidemiology*
Carcinoma, Hepatocellular / surgery
Carcinoma, Hepatocellular / therapy*
Catheter Ablation / methods
Chemoembolization, Therapeutic / methods
Hepatectomy / methods
Hepatitis B / prevention & control
Hepatitis B Vaccines / therapeutic use
Hepatitis C / prevention & control
Humans
Incidence
Liver Neoplasms / drug therapy
Liver Neoplasms / epidemiology*
Liver Neoplasms / surgery
Liver Neoplasms / therapy*
Liver Transplantation
Prevalence
Prognosis
Risk Factors
Survival Rate
United States / epidemiology

Substances

Hepatitis B Vaccines